Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial, The Lancet Diabetes & Endocrinology, August 2019, Elsevier,
DOI: 10.1016/s2213-8587(19)30158-5.
You can read the full text:

Read

Contributors

The following have contributed to this page